english.prescrire.org > Positions > Regulatory issues

Positions > Theme:

Regulatory issues

Drugs regulatory bodies ought to be the public’s principal defence against medicines that are useless, unproven or downright dangerous. Yet regulators increasingly depend upon financing from the pharmaceutical industry itself.  

Sending the wrong signals

Gambling with patients’ well-being

WHO is mandated at last to do essential biomedical research

Patients' interests first

What companies want



Demanding higher standards

Premature marketing authorisation: danger


Post-market studies: broken promises

Rare diseases: more new drugs, mixed results

Nutritional health warnings: just for show

Risk management plans: far from reassuring

Distinct and separate roles